Skip to main content

Improving COgnition in Down syndrome

Objective

Cognitive disabilities in individuals with Down syndrome (DS), also known as Trisomy 21, have no approved pharmacological treatment and represent a significant burden on DS individuals, their families and the healthcare system.
The ICOD project will deliver a clinical proof of concept for a new therapy of cognitive deficits in DS by performing first in humans (phase I) and clinical efficacy (Phase II) studies with AEF0217.
AEF0217 is a new chemical entity which offers a unique opportunity to treat cognitive deficits in DS. AEF0217 targets the CB1 receptor, a hyperactivity of which has been recently linked to cognitive deficit in DS. AEF0217 belongs to a new pharmacological class, named signalling specific inhibitors of the CB1 receptor (CB1-SSi), which allows to reverse cognitive deficit in animal models of DS. Because of its innovative MOA, AEF0217 is able to reduce selectively a hyperactivity of the CB1 without modifying the basal activity of this receptor and consequently without inducing behavioural side effects.
The overarching goal of the ICOD project is to make this innovative first-in-class drug available for DS individuals 7 years after clinical development initiation.

Call for proposal

H2020-SC1-2020-Two-Stage-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

CONSORCIO MAR PARC DE SALUT DE BARCELONA
Address
Paseo Maritim 25-29
08003 Barcelona
Spain
Activity type
Research Organisations
EU contribution
€ 1 448 917

Participants (5)

AELIS FARMA
France
EU contribution
€ 3 353 422,50
Address
Institut Francois Magendie, 146 Rue
33077 Bordeaux
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Associazione Oasi Maria SS. Onlus
Italy
EU contribution
€ 387 500
Address
Via Conte Ruggero 73
94018 Troina
Activity type
Other
INSTITUT JEROME LEJEUNE
France
EU contribution
€ 287 500
Address
31 Rue Galande
75725 Paris
Activity type
Research Organisations
CENTRE HOSPITALIER UNIVERSITAIRE SAINT ETIENNE - CHU
France
EU contribution
€ 256 250
Address

42055 Saint Etienne
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SERVICIO MADRILENO DE SALUD
Spain
EU contribution
€ 256 250
Address
Plaza Carlos Trias Bertran 7
28020 Madrid
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)